Creative Peptides has launched its synthetic peptide APIs for both researchers and manufacturers who are involved in the field of drug discovery and development. Only peptides synthesised under strict management and regulations can serve the pharmaceutical industry.
US-based Creative Peptides is an outsource for pharmaceutical agent synthesis. The company states that large scale custom peptide synthesis is its strength. A representative from the company said: “Liquid phase synthesis is frequently used; however, recently the solid phase synthesis method has become more favoured because of its unmatched advantages in reducing the difficulty of purification of product.”
To make sure that the synthetic peptide APIs manufactured are in compliance with the current available regulatory direction and expectations, all the steps are designed and strictly carried out under the guidance of the US Pharmacopeia (USP) Therapeutic Peptides Expert Panel. All quality attributes to be considered for successful synthetic peptide APIs development are carefully studied and assessed.
A total of more than 100 peptides and related products are available from grams to kgs and under cGMP (current Good Manufacturing Practice) standards. These peptide APIs are broadly used in the fields of cancer, cardiovascular, and diabetes research.
